Both diabetic and healthy Treg can be expanded with comparable purity and yield <i>in vitro</i>.

<p>CD4⁺CD25⁺CD127^−/lo Treg, electronically sorted using FACS from diabetic patients and healthy subjects, were activated in vitro using anti-CD3/anti-CD28-coated beads plus recombinant human IL-2. Expanded Treg were stained with CD4, CD25 and Foxp3 antibodies and analyzed by FACS on day 7 (D7) and day 14 (D14) following activation. (<b>A</b>) FACS analyses of CD4 and Foxp3 expression of expanded Treg on D7 and D14. The representative results were from cells obtained from one individual of each subject group. (<b>B</b>) Collective analyses of the purity and expansion fold of expanded Treg cells in each group on D7 and D14.